Expertise in
33
conditions

Dr. Jeanne M. Palmer

Hematology Oncology | Transplant Surgery
Mayo Clinic Arizona
5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
Offers Telehealth
21 Years of Experience
Expertise in
33
conditions
Mayo Clinic Arizona
5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeanne Palmer is a Hematologist Oncology specialist and a Transplant Surgeon in Phoenix, Arizona. Dr. Palmer has been practicing medicine for over 21 years is highly rated in 33 conditions, according to our data. Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 144 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Licenses
Internal Medicine in WI
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

MAYO CLINIC ARIZONA
5779 E Mayo Blvd, Speciality Building, Phoenix, AZ 85054
Other Locations
MAYO CLINIC ARIZONA
5701 E Mayo Blvd, Phoenix, AZ 85054
MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)
Enrollment Status: Completed
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Enasidenib
Study Phase: Phase 2
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of P1101 in Early Myelofibrosis
Phase II Study of P1101 in Early Myelofibrosis
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Other, Biological
Study Drug: Ropeginterferon Alfa-2B
Study Phase: Phase 2
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
View 4 Less Clinical Trials

144 Total Publications

Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials.
Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials.
Journal: Haematologica
Published: February 13, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Januario E. Castro
Hematology Oncology | Transplant Surgery | Hematology
Expertise in
25
conditions
Dr. Januario E. Castro
Hematology Oncology | Transplant Surgery | Hematology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (10.7 mi)
480-301-8000
Languages Spoken:
English
Offers Telehealth

Januario Castro is a Hematologist Oncology specialist and a Transplant Surgeon in Scottsdale, Arizona. Dr. Castro is highly rated in 25 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
14
conditions
Dr. Nandita Khera
Hematology Oncology | Hematology | Oncology
Expertise in
14
conditions
Dr. Nandita Khera
Hematology Oncology | Hematology | Oncology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (10.7 mi)
480-301-8000
Languages Spoken:
English, Hindi
See accepted insurances

Nandita Khera is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Khera is highly rated in 14 conditions, according to our data. Her top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
12
conditions
Dr. Amit K. Mathur
Transplant Surgery | General Surgery
Expertise in
12
conditions
Dr. Amit K. Mathur
Transplant Surgery | General Surgery

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (0.1 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amit Mathur is a Transplant Surgeon and a General Surgeon in Phoenix, Arizona. Dr. Mathur is highly rated in 12 conditions, according to our data. His top areas of expertise are Liver Failure, Hepatitis, Hepatic Cystic Hamartoma, Liver Transplant, and Kidney Transplant. Dr. Mathur is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Palmer's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 16 Advanced Conditions
View All 65 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile